Uterine Cervix CancerPhase 2NCT06331468
Hypofractionated Radiochemotherapy
Cisplatin, intensity modulated radiation therapy (IMRT), high-dose-rate (HDR) brachytherapy
40 Phase 2 studies recruiting right now, most recently updated first.
Open the Phase 2 page · a list of only those studies
Triangle is made by Triangle Health, Inc.
Ovary and gynecologic40 studies
Uterine Cervix CancerPhase 2NCT06331468
Cisplatin, intensity modulated radiation therapy (IMRT), high-dose-rate (HDR) brachytherapy
Uterine LeiomyosarcomaPhase 2NCT05649956
Letrozole
Cervical CancerPhase 2NCT05838521
Sacituzumab govitecan
Ovarian CancerPhase 2NCT04918186Papers
Durvalumab, BA3011, BA3021, ENB003
Recurrent Endometrial CarcinomaPhase 2NCT04469764
Abemaciclib, Anastrozole, Letrozole
Ovarian CancerPhase 2NCT06906341
Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg
Ovarian CancerPhase 2NCT04606914
mirvetuximab soravtansine (MIRV; IMGN853)
Ovary CancerPhase 2NCT05887609
Mirvetuximab Soravtansine-gynx, Olaparib
Platinum-resistant Ovarian CancerPhase 2NCT06710288
Gemcitabine, N-803, M-CENK
Ovarian CancerPhase 2NCT05952453
Carboplatin, olaparibp, embro
Endometrial CancerPhase 2NCT03832361
IMGN853
Ovarian NeoplasmsPhase 2NCT04641247
Niraparib
HER2/Neu+ Uterine Serous CarcinomaPhase 2NCT02491099Papers
Afatinib
Platinum-Resistant Fallopian Tube CarcinomaPhase 2NCT05538091
Vismodegib, Atezolizumab
Ovarian CancerPhase 2NCT05071937
ZEN003694, Talazoparib
Cervical CancersPhase 2NCT07022470
3-Fraction HDR Brachytherapy, 4-Fraction HDR Brachytherapy